- Home
- CYBN vs BDSX Comparison
CYBN vs BDSX Comparison
Compare CYBN & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- BDSX
- Stock Information
- Founded
- CYBN 2019
- BDSX 2005
- Country
- CYBN Canada
- BDSX United States
- Employees
- CYBN N/A
- BDSX N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- BDSX Precision Instruments
- Sector
- CYBN Health Care
- BDSX Health Care
- Exchange
- CYBN Nasdaq
- BDSX Nasdaq
- Market Cap
- CYBN 127.3M
- BDSX 115.4M
- IPO Year
- CYBN N/A
- BDSX 2020
- Fundamental
- Price
- CYBN $7.96
- BDSX $0.30
- Analyst Decision
- CYBN Strong Buy
- BDSX Strong Buy
- Analyst Count
- CYBN 4
- BDSX 5
- Target Price
- CYBN $86.00
- BDSX $1.75
- AVG Volume (30 Days)
- CYBN 326.6K
- BDSX 25.3M
- Earning Date
- CYBN 06-25-2025
- BDSX 05-13-2025
- Dividend Yield
- CYBN N/A
- BDSX N/A
- EPS Growth
- CYBN N/A
- BDSX N/A
- EPS
- CYBN N/A
- BDSX N/A
- Revenue
- CYBN N/A
- BDSX $74,463,000.00
- Revenue This Year
- CYBN N/A
- BDSX $19.92
- Revenue Next Year
- CYBN N/A
- BDSX $29.03
- P/E Ratio
- CYBN N/A
- BDSX N/A
- Revenue Growth
- CYBN N/A
- BDSX 35.76
- 52 Week Low
- CYBN $4.81
- BDSX $0.17
- 52 Week High
- CYBN $13.88
- BDSX $2.04
- Technical
- Relative Strength Index (RSI)
- CYBN 61.23
- BDSX 38.36
- Support Level
- CYBN $7.00
- BDSX $0.31
- Resistance Level
- CYBN $8.50
- BDSX $0.37
- Average True Range (ATR)
- CYBN 0.53
- BDSX 0.07
- MACD
- CYBN 0.15
- BDSX 0.01
- Stochastic Oscillator
- CYBN 76.00
- BDSX 37.90
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.